Stem cell culture conditions and stability: A joint workshop of the PluriMes Consortium and Pluripotent Stem Cell Platform

Glyn N. Stacey; Peter W. Andrews; Ivana Barbaric; Charlotta Boiers; Amit Chandra; Giulio Cossu; Lynn Csontos; Thomas Jr Frith; Jason A. Halliwell; Zoe Hewitt; Mark McCall; Harry D. Moore; Malin Parmar; M. Beatrice Panico; Venkat Pisupati; Valentin P. Shichkin; Alison R. Stacey; Francesco S. Tedesco; Oliver Thompson; Ravenska Wagey

doi:10.2217/rme-2019-0001

Stem cell culture conditions and stability: A joint workshop of the PluriMes Consortium and Pluripotent Stem Cell Platform

Glyn N. Stacey^*, Peter W. Andrews, Ivana Barbaric, Charlotta Boiers, Amit Chandra, Giulio Cossu, Lynn Csontos, Thomas Jr Frith, Jason A. Halliwell, Zoe Hewitt, Mark McCall, Harry D. Moore, Malin Parmar, M. Beatrice Panico, Venkat Pisupati, Valentin P. Shichkin, Alison R. Stacey, Francesco S. Tedesco, Oliver Thompson, Ravenska Wagey

^*Corresponding author for this work

Division of Cell Matrix Biology & Regenerative Medicine (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

Human stem cells have the potential to transform medicine. However, hurdles remain to ensure that manufacturing processes produce safe and effective products. A thorough understanding of the biological processes occurring during manufacture is fundamental to assuring these qualities and thus, their acceptability to regulators and clinicians. Leaders in both human pluripotent and somatic stem cells, were brought together with experts in clinical translation, biomanufacturing and regulation, to discuss key issues in assuring appropriate manufacturing conditions for delivery of effective and safe products from these cell types. This report summarizes the key issues discussed and records consensus reached by delegates and emphasizes the need for accurate language and nomenclature in the scientific discourse around stem cells.

Original language	English
Pages (from-to)	243-255
Number of pages	13
Journal	Regenerative Medicine
Volume	14
Issue number	3
Early online date	2 Apr 2019
DOIs	https://doi.org/10.2217/rme-2019-0001
Publication status	Published - 2019

Keywords

cell therapy
cell-based medicines
characterization regulation
clinical trial
manufacturing
mesenchymal cells
pluripotent stem cells
regenerative medicine

Access to Document

10.2217/rme-2019-0001

Cite this

Stacey, G. N., Andrews, P. W., Barbaric, I., Boiers, C., Chandra, A., Cossu, G., Csontos, L., Frith, T. J., Halliwell, J. A., Hewitt, Z., McCall, M., Moore, H. D., Parmar, M., Panico, M. B., Pisupati, V., Shichkin, V. P., Stacey, A. R., Tedesco, F. S., Thompson, O., & Wagey, R. (2019). Stem cell culture conditions and stability: A joint workshop of the PluriMes Consortium and Pluripotent Stem Cell Platform. Regenerative Medicine, 14(3), 243-255. https://doi.org/10.2217/rme-2019-0001

@article{952cea458afc4e69a2baee8a49560aa5,

title = "Stem cell culture conditions and stability: A joint workshop of the PluriMes Consortium and Pluripotent Stem Cell Platform",

abstract = "Human stem cells have the potential to transform medicine. However, hurdles remain to ensure that manufacturing processes produce safe and effective products. A thorough understanding of the biological processes occurring during manufacture is fundamental to assuring these qualities and thus, their acceptability to regulators and clinicians. Leaders in both human pluripotent and somatic stem cells, were brought together with experts in clinical translation, biomanufacturing and regulation, to discuss key issues in assuring appropriate manufacturing conditions for delivery of effective and safe products from these cell types. This report summarizes the key issues discussed and records consensus reached by delegates and emphasizes the need for accurate language and nomenclature in the scientific discourse around stem cells.",

keywords = "cell therapy, cell-based medicines, characterization regulation, clinical trial, manufacturing, mesenchymal cells, pluripotent stem cells, regenerative medicine",

author = "Stacey, {Glyn N.} and Andrews, {Peter W.} and Ivana Barbaric and Charlotta Boiers and Amit Chandra and Giulio Cossu and Lynn Csontos and Frith, {Thomas Jr} and Halliwell, {Jason A.} and Zoe Hewitt and Mark McCall and Moore, {Harry D.} and Malin Parmar and Panico, {M. Beatrice} and Venkat Pisupati and Shichkin, {Valentin P.} and Stacey, {Alison R.} and Tedesco, {Francesco S.} and Oliver Thompson and Ravenska Wagey",

year = "2019",

doi = "10.2217/rme-2019-0001",

language = "English",

volume = "14",

pages = "243--255",

journal = "Regenerative Medicine",

issn = "1746-0751",

publisher = "Taylor & Francis",

number = "3",

}

Stacey, GN, Andrews, PW, Barbaric, I, Boiers, C, Chandra, A, Cossu, G, Csontos, L, Frith, TJ, Halliwell, JA, Hewitt, Z, McCall, M, Moore, HD, Parmar, M, Panico, MB, Pisupati, V, Shichkin, VP, Stacey, AR, Tedesco, FS, Thompson, O & Wagey, R 2019, 'Stem cell culture conditions and stability: A joint workshop of the PluriMes Consortium and Pluripotent Stem Cell Platform', Regenerative Medicine, vol. 14, no. 3, pp. 243-255. https://doi.org/10.2217/rme-2019-0001

TY - JOUR

T1 - Stem cell culture conditions and stability

T2 - A joint workshop of the PluriMes Consortium and Pluripotent Stem Cell Platform

AU - Stacey, Glyn N.

AU - Andrews, Peter W.

AU - Barbaric, Ivana

AU - Boiers, Charlotta

AU - Chandra, Amit

AU - Cossu, Giulio

AU - Csontos, Lynn

AU - Frith, Thomas Jr

AU - Halliwell, Jason A.

AU - Hewitt, Zoe

AU - McCall, Mark

AU - Moore, Harry D.

AU - Parmar, Malin

AU - Panico, M. Beatrice

AU - Pisupati, Venkat

AU - Shichkin, Valentin P.

AU - Stacey, Alison R.

AU - Tedesco, Francesco S.

AU - Thompson, Oliver

AU - Wagey, Ravenska

PY - 2019

Y1 - 2019

N2 - Human stem cells have the potential to transform medicine. However, hurdles remain to ensure that manufacturing processes produce safe and effective products. A thorough understanding of the biological processes occurring during manufacture is fundamental to assuring these qualities and thus, their acceptability to regulators and clinicians. Leaders in both human pluripotent and somatic stem cells, were brought together with experts in clinical translation, biomanufacturing and regulation, to discuss key issues in assuring appropriate manufacturing conditions for delivery of effective and safe products from these cell types. This report summarizes the key issues discussed and records consensus reached by delegates and emphasizes the need for accurate language and nomenclature in the scientific discourse around stem cells.

AB - Human stem cells have the potential to transform medicine. However, hurdles remain to ensure that manufacturing processes produce safe and effective products. A thorough understanding of the biological processes occurring during manufacture is fundamental to assuring these qualities and thus, their acceptability to regulators and clinicians. Leaders in both human pluripotent and somatic stem cells, were brought together with experts in clinical translation, biomanufacturing and regulation, to discuss key issues in assuring appropriate manufacturing conditions for delivery of effective and safe products from these cell types. This report summarizes the key issues discussed and records consensus reached by delegates and emphasizes the need for accurate language and nomenclature in the scientific discourse around stem cells.

KW - cell therapy

KW - cell-based medicines

KW - characterization regulation

KW - clinical trial

KW - manufacturing

KW - mesenchymal cells

KW - pluripotent stem cells

KW - regenerative medicine

U2 - 10.2217/rme-2019-0001

DO - 10.2217/rme-2019-0001

M3 - Article

C2 - 30938271

AN - SCOPUS:85064638415

SN - 1746-0751

VL - 14

SP - 243

EP - 255

JO - Regenerative Medicine

JF - Regenerative Medicine

IS - 3

ER -

Stem cell culture conditions and stability: A joint workshop of the PluriMes Consortium and Pluripotent Stem Cell Platform

Abstract

Keywords

Access to Document

Fingerprint

Cite this